RDInvesting Provides Investors with Free In-Depth Equity Reports on CVS, GEVA, GNC and SPPI

Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us free at http://www.rdinvesting.com/ and get exclusive access to our numerous stock reports and market updates.

CVS Caremark Corporation (NYSE:CVS - News) shares declined 0.26 percent to close at $56.73 a share Monday. The stock traded between $56.34 and $57.12 on volume of 4.33 million shares traded. Analysts at Jefferies have recently initiated coverage on the company with a "buy" rating and a price target of $71.00. Shares of CVS Caremark have gained approximately 17.0 percent year-to-date.

Find out more about CVS Caremark including full access to the free equity report at:
www.RDInvesting.com/CVS

Synageva BioPharma Corp. (NASDAQ:GEVA - News) shares declined 1.17 percent to close at $67.17 a share Monday. The stock traded between $67.01 and $69.10 on volume of 225,024 shares traded. Analysts at Wedbush have recently downgraded the company’s rating to "neutral" from "outperform". Shares of Synageva BioPharma have gained approximately 47.0 percent year-to-date.

Find out more about Synageva BioPharma including full access to the free equity report at:
www.RDInvesting.com/GEVA

GNC Holdings Inc. (NYSE:GNC - News) shares declined 1.07 percent to close at $54.46 a share Monday. The stock traded between $54.03 and $54.78 on volume of 507,846 shares traded. Analysts at Jefferies have recently initiated coverage on the company with a "buy" rating and a price target of $68.00. Shares of GNC Holdings have gained approximately 63.0 percent year-to-date.

Find out more about GNC Holdings including full access to the free equity report at:
www.RDInvesting.com/GNC

Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI - News) shares increased 2.0 percent to close at $8.66 a share Monday. The stock traded between $8.53 and $8.91 on volume of 1.22 million shares traded. Analysts at HC Wainwright have recently initiated coverage on the company with a "buy" rating.

Find out more about Spectrum Pharmaceuticals including full access to the free equity report at:
www.RDInvesting.com/SPPI

Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Research Driven Investing has no financial relationship with any company whose stock is mentioned in this release.

Contact:
Research Driven Investing
info@rdinvesting.com